A Prospective Study of Plasma Vitamin D Metabolites, Vitamin D Receptor Polymorphisms, and Prostate Cancer
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Vitamin D insufficiency is a common public health problem nationwide. Circulating 25-hydroxyvitamin D3 (25[OH]D), the most commonly used index of vitamin D status, is converted to the active hormone 1,25 dihydroxyvitamin D3 (1,25[OH]2D), which, operating through the vitamin D receptor (VDR), inhibits in vitro cell proliferation, induces differentiation and apoptosis, and may protect against prostate cancer. Despite intriguing results from laboratory studies, previous epidemiological studies showed inconsistent associations of circulating levels of 25(OH)D, 1,25(OH)2D, and several VDR polymorphisms with prostate cancer risk. Few studies have explored the joint association of circulating vitamin D levels with VDR polymorphisms. METHODS AND FINDINGS: During 18 y of follow-up of 14,916 men initially free of diagnosed cancer, we identified 1,066 men with incident prostate cancer (including 496 with aggressive disease, defined as stage C or D, Gleason 7-10, metastatic, and fatal prostate cancer) and 1,618 cancer-free, age- and smoking-matched control participants in the Physicians' Health Study. We examined the associations of prediagnostic plasma levels of 25(OH)D and 1,25(OH)2D, individually and jointly, with total and aggressive disease, and explored whether relations between vitamin D metabolites and prostate cancer were modified by the functional VDR FokI polymorphism, using conditional logistic regression. Among these US physicians, the median plasma 25(OH)D levels were 25 ng/ml in the blood samples collected during the winter or spring and 32 ng/ml in samples collected during the summer or fall. Nearly 13% (summer/fall) to 36% (winter/spring) of the control participants were deficient in 25(OH)D (<20 ng/ml) and 51% (summer/fall) and 77% (winter/spring) had insufficient plasma 25(OH)D levels (<32 ng/ml). Plasma levels of 1,25(OH)2D did not vary by season. Men whose levels for both 25(OH)D and 1,25(OH)2D were below (versus above) the median had a significantly increased risk of aggressive prostate cancer (odds ratio [OR] = 2.1, 95% confidence interval [CI] 1.2-3.4), although the interaction between the two vitamin D metabolites was not statistically significant (pinteraction = 0.23). We observed a significant interaction between circulating 25(OH)D levels and the VDR FokI genotype (pinteraction < 0.05). Compared with those with plasma 25(OH)D levels above the median and with the FokI FF or Ff genotype, men who had low 25(OH)D levels and the less functional FokI ff genotype had increased risks of total (OR = 1.9, 95% CI 1.1-3.3) and aggressive prostate cancer (OR = 2.5, 95% CI 1.1-5.8). Among men with plasma 25(OH)D levels above the median, the ff genotype was no longer associated with risk. Conversely, among men with the ff genotype, high plasma 25(OH)D level (above versus below the median) was related to significant 60% approximately 70% lower risks of total and aggressive prostate cancer. CONCLUSIONS: Our data suggest that a large proportion of the US men had suboptimal vitamin D status (especially during the winter/spring season), and both 25(OH)D and 1,25(OH)2D may play an important role in preventing prostate cancer progression. Moreover, vitamin D status, measured by 25(OH)D in plasma, interacts with the VDR FokI polymorphism and modifies prostate cancer risk. Men with the less functional FokI ff genotype (14% in the European-descent population of this cohort) are more susceptible to this cancer in the presence of low 25(OH)D status.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Final Report on the Aspirin Component of the Ongoing Physicians' Health Study
Steering Committee of the Physicians' Health Study Research Group* (1989) · New England Journal of Medicine · doi:10.1056/nejm198907203210301 · Cited by 2,264
Prediction of bone density from vitamin D receptor alleles
Morrison, N. A., Qi, J. C., Tokita, A., Kelly, P. J., Crofts, L., Nguyen, T. V., Sambrook, P. N., & Eisman, J. A. (1994) · Nature · doi:10.1038/367284a0 · Cited by 1,919
Genetics and biology of vitamin D receptor polymorphisms
Uitterlinden, A. G., Fang, Y., van Meurs, J. B. J., Pols, H. A. P., & van Leeuwen, J. P. T. M. (2004) · Gene · doi:10.1016/j.gene.2004.05.014 · Cited by 1,539
Hollis, B. W. (2005) · The Journal of Nutrition · doi:10.1093/jn/135.2.317 · Cited by 1,162
Arai, H., Miyamoto, K.-I., Taketani, Y., Yamamoto, H., Iemori, Y., Morita, K., Tonai, T., Nishisho, T., Mori, S., & Takeda, E. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.6.915 · Cited by 651
Hanchette, C. L., & Schwartz, G. G. (1992) · Cancer · doi:10.1002/1097-0142(19921215)70:12<2861::aid-cncr2820701224>3.0.co;2-g · Cited by 645
Localized scleroderma-response to 1,25-dihydroxyvitamin D3
HUMBERT, P. G., DUPOND, J. L., ROCHEFORT, A., VASSELET, R., LUCAS, A., LAURENT, R., & AGACHE, P. (1990) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.1990.tb02127.x · Cited by 612
Benefits and requirements of vitamin D for optimal health: a review.
Grant, W. B., & Holick, M. F. (2005) · PubMed · Cited by 610
Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis).
Schwartz, G. G., & Hulka, B. S. (1990) · PubMed · Cited by 585
Assay Variation Confounds the Diagnosis of Hypovitaminosis D: A Call for Standardization
Binkley, N., Krueger, D., Cowgill, C. S., Plum, L., Lake, E., Hansen, K. E., DeLuca, H. F., & Drezner, M. K. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031979 · Cited by 577
Skowroński, R., Peehl, D. M., & Feldman, D. I. (1993) · Endocrinology · doi:10.1210/en.132.5.1952 · Cited by 494
Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland)
Ahonen, M. H., Tenkanen, L., Teppo, L., Hakama, M., & Tuohimaa, P. (2000) · Cancer Causes & Control · doi:10.1023/a:1008923802001 · Cited by 494
Determination of vitamin D status by radioimmunoassay with an 125I-labeled tracer
Hollis, B. W., Kamerud, J. Q., Selvaag, S. R., Lorenz, J. D., & Napoli, J. L. (1993) · Clinical Chemistry · doi:10.1093/clinchem/39.3.529 · Cited by 432
Tuohimaa, P., Tenkanen, L., Ahonen, M., Lumme, S., Jellum, E., Hallmans, G., Stattin, P., Harvei, S., Hakulinen, T., Luostarinen, T., et al. (2004) · International Journal of Cancer · doi:10.1002/ijc.11375 · Cited by 428
Functionally relevant polymorphisms in the human nuclear vitamin D receptor gene
Kerr Whitfield, G., Remus, L. S., Jurutka, P. W., Zitzer, H., Oza, A. K., Dang, H. T. L., Haussler, C. A., Galligan, M. A., Thatcher, M. L., Dominguez, C. E., et al. (2001) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(01)00406-3 · Cited by 413
Jurutka, P. W. (2000) · Molecular Endocrinology · doi:10.1210/me.14.3.401 · Cited by 395
Vitamin D and prostate cancer: a prediagnostic study with stored sera.
Corder, E. H., Guess, H. A., Hulka, B. S., FRIEDMAN, G. D., Sadler, M. C., Vollmer, R. T., Lobaugh, B., Drezner, M. K., Vogelman∥, J. H., & Orentreich∥, N. (1993) · PubMed · Cited by 356
The prevalence of hypovitaminosis D among US adults: data from the NHANES III.
Zadshir, A., Tareen, N. G., Pan, D., Norris, K. C., & Martins, D. (2005) · PubMed · Cited by 280
The Vitamin D Receptor Gene Start Codon Polymorphism: A Functional Analysis of Fok I Variants
Gross, C., Krishnan, A. V., Malloy, P. J., Eccleshall, T. R., Zhao, X.-Y., & Feldman, D. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.11.1691 · Cited by 237
Ma, J., Stampfer, M. J., Gann, P. H., Hough, H., Giovannucci, E. L., Kelsey, K. T., Hennekens, C. H., & Hunter, D. J. (1998) · PubMed · Cited by 235
Self-citationSun Exposure, Vitamin D Receptor Gene Polymorphisms, and Risk of Advanced Prostate Cancer
John, E. M., Schwartz, G. G., Koo, J., Van Den Berg, D., & Ingles, S. A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3134 · Cited by 235
Plasma 1,25-Dihydroxy- and 25-Hydroxyvitamin D and Subsequent Risk of Prostate Cancer
Platz, E. A., Leitzmann, M. F., Hollis, B. W., Willett, W. C., & Giovannucci, E. (2004) · Cancer Causes & Control · doi:10.1023/b:caco.0000024245.24880.8a · Cited by 229
Self-citationHsu, J. Y., Feldman, D., McNeal, J. E., & Peehl, D. M. (2001) · PubMed · Cited by 212
Lokeshwar, B. L., Schwartz, G. G., Selzer, M. G., Burnstein, K. L., Zhuang, S. H., Block, N. L., & Binderup, L. (1999) · PubMed · Cited by 200
Dietary influences of 1,25(OH)2 vitamin D in relation to prostate cancer: A hypothesis
Giovannucci, E. (1998) · Cancer Causes & Control · doi:10.1023/a:1008835903714 · Cited by 195
Self-citationSaijo, T., Ito, M., Takeda, E., Huq, A. H. M. M., Naito, E., Yokota, I., Sone, T., Pike, J. W., & Kuroda, Y. (1991) · Europe PMC (PubMed Central) · Cited by 192
Vitamin D Insufficiency in North America
Hanley, D. A., & Davison, K. S. (2005) · The Journal of Nutrition · doi:10.1093/jn/135.2.332 · Cited by 190
Stewart, L. V., & Weigel, N. L. (2004) · Experimental Biology and Medicine · doi:10.1177/153537020422900401 · Cited by 189
Colin, E. M., Weel, A. E. A. M., Uitterlinden, A. G., Buurman, C. J., Birkenhäger, J. C., Pols, H. A. P., & Van Leeuwen, J. P. T. M. (2000) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2000.00909.x · Cited by 188
Circulating vitamin D metabolites in relation to subsequent development of prostate cancer.
Gann, P. H., Ma, J., Hennekens, C. H., Hollis, B. W., Haddad, J. G., & Stampfer, M. J. (1996) · PubMed · Cited by 185
Self-citationProstate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States)
Braun, M. M., Helzlsouer, K. J., Hollis, B. W., & Comstock, G. W. (1995) · Cancer Causes and Control · doi:10.1007/bf00051795 · Cited by 183
1 alpha,25-Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells.
Schwartz, G. G., Wang, M. H., Zang, M., Singh, R. K., & Siegal, G. P. (1997) · PubMed · Cited by 180
Nomura, A. M. Y., Stemmermann, G. N., Lee, J., Kolonel, L. N., Chen, T. C., Turner, A., & Holick, M. F. (1998) · Cancer Causes & Control · doi:10.1023/a:1008875819232 · Cited by 161
Quantification of circulating 1,25-dihydroxyvitamin D by radioimmunoassay with 125I-labeled tracer
Hollis, B. W., Kamerud, J., Kurkowski, A., Beaulieu, J., & Napoli, J. L. (1996) · Clinical Chemistry · doi:10.1093/clinchem/42.4.586 · Cited by 145
Prostatic 25‐hydroxyvitamin D‐1α‐hydroxylase and its implication in prostate cancer
Chen, T. C., Wang, L., Whitlatch, L. W., Flanagan, J. N., & Holick, M. F. (2003) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10342 · Cited by 138
VITAMIN D IN HEALTH AND DISEASE: Vitamin D and the Epidemiology of Prostate Cancer
Schwartz, G. G. (2005) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2005.18403.x · Cited by 116
Plasma levels of 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and the risk of prostate cancer
Jacobs, E. T., Giuliano, A. R., Martínez, M. E., Hollis, B. W., Reid, M. E., & Marshall, J. R. (2004) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2004.03.063 · Cited by 108
Blutt, S. E., & Weigel, N. L. (1999) · Experimental Biology and Medicine · doi:10.1046/j.1525-1373.1999.d01-60.x · Cited by 72
Role of the vitamin D‐endocrine system in the pathophysiology of postmenopausal osteoporosis
Riggs, B. L. (2003) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10345 · Cited by 55
Luscombe, C. J. (2001) · Carcinogenesis · doi:10.1093/carcin/22.9.1343 · Cited by 46
Diagnosis, Staging, and Surgical Treatment of Prostatic Carcinoma
Catàlona, W. J., & Avioli, L. V. (1987) · Archives of Internal Medicine · doi:10.1001/archinte.1987.00370020179060 · Cited by 39
Cited by
Vitamin D and Human Health: Lessons from Vitamin D Receptor Null Mice
Bouillon, R., Carmeliet, G., Verlinden, L., van Etten, E., Verstuyf, A., Luderer, H. F., Lieben, L., Mathieu, C., & Demay, M. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0004 · Cited by 1,783
The Epidemiology of Prostate Cancer
Pernar, C. H., Ebot, E. M., Wilson, K. M., & Mucci, L. A. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030361 · Cited by 773
Self-citationGandini, S., Boniol, M., Haukka, J., Byrnes, G., Cox, B., Sneyd, M. J., Mullie, P., & Autier, P. (2011) · International Journal of Cancer · doi:10.1002/ijc.25439 · Cited by 499
Vitamin D for Cancer Prevention: Global Perspective
Garland, C. F., Gorham, E. D., Mohr, S. B., & Garland, F. C. (2009) · Annals of Epidemiology · doi:10.1016/j.annepidem.2009.03.021 · Cited by 438
Chung, M., Lee, J., Terasawa, T., Lau, J., & Trikalinos, T. A. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-12-201112200-00005 · Cited by 415
Metadata
- Authors
- Li, H., Stampfer, M. J., Hollis, J. B. W., Mucci, L. A., Gaziano, J. M., Hunter, D., Giovannucci, E. L., & Ma, J.
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2007-03-20
- Volume
- 4
- Issue
- 3
- Pages
- e103
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W2113143740
- Cited by
- 290
- References
- 41
- FWCI
- 18.44
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.